Multisystem Inflammatory Syndrome (MIS-C) is a complication of SARS-CoV-2 infection in children, which occurs 3-4 weeks after the acute infection due to a cytokine storm. Intravenous immunoglobulins (IVIG) and Steroids (Methyl prednisolone) are the main stay of treatment. However, we are yet to fully understand the immumopathological role of these treatments in MIS-C. Most of the clinicians and institutions around the world use both IVIG and Steroids, but few use either one of them. Early reports and experience of paediatricians suggest that different regimen seem to work equally. However, there is no evidence in identifying the right treatment pathway. Evidence is therefore, urgently needed to support treatment decisions for children with MIS-C. Through this study, we aim to evaluate the efficacy of different treatment regimen followed in various Paediatric intensive care units across Chennai, India in the management of MIS-C to reach a consensus.

Stored plasma samples from children aged 0 to ≤ 18 years, admitted to PICUs of various hospitals across Chennai, with MIS-C will be included in the study. We will be analysing the following on stored samples:

·         IL-6, IFNγ, TNFα, IL-2, IL-10, MIP-1a, GM-CSF, MCP-1, MI-1a

·         Neutrophil elastase, plasmin and alpha-1-antitrypsin

·         ProBnP and Troponin

1) IVIG plus MPS; 2) IVIG alone; 3) MPS alone